Praxis Precision Medicines Provides Vormatrigine Program Update
Praxis Precision Medicines announced that its Phase 2/3 POWER1 study for vormatrigine failed to meet the primary endpoint of percent change in monthly seizure frequency. The study did meet the secondary endpoint of a 50% response rate, with more pronounced seizure reduction observed on the higher 30 mg dose during the second half of the trial.
Key figures
- Drug Name
- vormatrigine
- Phase Of Trial
- Phase 2/3
- Ole transition rate
- ~90%
- Primary endpoint met
- No
- Secondary endpoint met
- Yes
- Secondary endpoint description
- 50% response rate
- Adverse event discontinuation rate
- <10%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.